Free Trial
→ Elon’s Biggest Launch Ever: 15x Bigger Than SpaceX (From InvestorPlace) (Ad)tc pixel Free CDTX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Cidara Therapeutics (CDTX) Financials

Cidara Therapeutics logo
Compare
Annual Income Statements for Cidara Therapeutics

Annual Income Statements for Cidara Therapeutics

This table shows Cidara Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -12 -32 -48 -56 -69 -41 -75 -42 -34 -23 -170
Consolidated Net Income / (Loss)		 -12 -32 -48 -56 -59 -41 -72 -42 -34 -23 -170
Net Income / (Loss) Continuing Operations		 -12 -32 -48 -56 -59 -41 -72 -42 -34 -25 -170
Total Pre-Tax Income 		-12 -32 -48 -56 -59 -41 -72 -42 -33 -25 -170
Total Operating Income		 -12 -32 -48 -56 -63 -42 -72 -42 -34 -27 -176
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 21 12 50 64 23 1.28
Total Revenue		 0.00 0.00 0.00 0.00 0.00 21 12 50 64 23 1.28
Operating Revenue		 - - - 0.00 0.00 21 12 50 64 23 1.28
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 32 48 56 63 63 84 92 98 50 177
Selling, General & Admin Expense		 3.31 8.84 13 13 14 16 16 19 21 14 21
Research & Development Expense		 8.32 23 36 43 49 46 68 73 77 37 157
Total Other Income / (Expense), net		 -0.27 0.12 0.27 -0.01 4.27 0.63 -0.26 -0.21 0.38 2.00 5.81
Interest & Investment Income		 -0.09 0.12 0.27 -0.01 0.63 0.22 -0.26 -0.21 0.19 2.00 5.81
Income Tax Expense		 - - - - - - - - 0.27 0.02 0.00
Net Income / (Loss) Discontinued Operations		 - - - - - - - - - 2.15 0.46
Basic Earnings per Share		 ($14.51) ($3.25) ($3.32) ($3.18) ($2.68) ($1.37) ($1.80) ($0.81) ($0.48) ($5.25) ($26.75)
Weighted Average Basic Shares Outstanding		 819.87K 9.92M 14.49M 17.50M 25.87M 29.93M 41.56M 52.45M 69.86M 4.37M 6.35M
Diluted Earnings per Share		 ($14.51) ($3.25) ($3.32) ($3.18) ($2.68) ($1.37) ($1.80) ($0.81) ($0.48) ($5.25) ($26.75)
Weighted Average Diluted Shares Outstanding		 819.87K 9.92M 14.49M 17.50M 25.87M 29.93M 41.56M 52.45M 69.86M 4.37M 6.35M
Weighted Average Basic & Diluted Shares Outstanding		 819.87K 9.92M 14.49M 17.50M 25.87M 29.93M 41.56M 68.15M 89.01M - 10.95M

Quarterly Income Statements for Cidara Therapeutics

This table shows Cidara Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 2.38 -14 -9.11 -2.58 -10 -91 -16 -52 -23 -26 -83
Consolidated Net Income / (Loss)		 3.01 -14 -9.11 -3.21 -10 -91 -16 -52 -23 -26 -83
Net Income / (Loss) Continuing Operations		 3.01 -6.17 -3.82 -18 -8.18 -94 -16 -50 -23 -26 -83
Total Pre-Tax Income 		3.01 -6.13 -3.86 -18 -8.18 -94 -16 -50 -23 -26 -83
Total Operating Income		 2.78 -6.75 -4.47 -19 -8.54 -96 -17 -52 -25 -27 -89
Total Gross Profit		 26 5.09 9.22 -17 0.97 0.30 0.00 -7.49 0.00 0.00 0.00
Total Revenue		 26 5.09 9.22 -17 0.97 0.30 0.00 -7.49 0.00 0.00 0.00
Operating Revenue		 26 5.09 9.22 -17 0.97 0.30 0.00 -7.49 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 23 12 14 1.49 9.52 96 17 45 25 27 89
Selling, General & Admin Expense		 4.46 3.18 3.30 2.64 3.60 4.75 4.97 3.34 6.18 6.50 8.10
Research & Development Expense		 19 8.66 10 -1.15 5.92 92 12 41 25 25 81
Other Operating Expenses / (Income)		 - - - - 0.00 0.00 0.00 - -5.51 -3.94 0.00
Total Other Income / (Expense), net		 0.23 0.62 0.61 0.53 0.37 1.77 1.86 1.81 1.79 1.67 5.40
Interest & Investment Income		 0.23 0.62 0.61 0.53 0.37 1.77 1.86 1.81 1.90 1.67 5.40
Other Income / (Expense), net		 - - - - 0.00 0.00 0.00 - -0.11 0.00 0.00
Net Income / (Loss) Discontinued Operations		 - -7.46 -5.28 - -2.15 3.00 -0.45 - 0.00 0.00 0.00
Basic Earnings per Share		 $0.60 ($3.02) ($2.02) ($0.59) ($2.28) ($19.99) ($2.45) ($8.24) ($1.66) ($1.65) ($3.10)
Weighted Average Basic Shares Outstanding		 3.93M 4.51M 4.51M 4.37M 4.54M 4.56M 6.53M 6.35M 14.18M 15.55M 26.88M
Diluted Earnings per Share		 $0.60 ($3.02) ($2.02) ($0.59) ($2.28) ($19.99) ($2.45) ($8.24) ($1.66) ($1.65) ($3.10)
Weighted Average Diluted Shares Outstanding		 5.06M 4.51M 4.51M 4.37M 4.54M 4.56M 6.53M 6.35M 14.18M 15.55M 26.88M
Weighted Average Basic & Diluted Shares Outstanding		 90.03M 90.25M 90.43M 0.00 4.56M 7.04M 7.05M 10.95M 12.97M 25.36M 31.44M

Annual Cash Flow Statements for Cidara Therapeutics

This table details how cash moves in and out of Cidara Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 23 40 23 -25 14 -14 -17 19 -30 3.05 160
Net Cash From Operating Activities		 -7.71 -26 -40 -50 -57 -29 -54 -25 -28 -22 -177
Net Cash From Continuing Operating Activities		 -7.71 -26 -40 -50 -57 -29 -54 -25 -28 -22 -177
Net Income / (Loss) Continuing Operations		 -12 -32 -48 -56 -59 -41 -72 -42 -34 -23 -170
Consolidated Net Income / (Loss)		 -12 -32 -48 -56 -59 -41 -72 -42 -34 -23 -170
Depreciation Expense		 0.18 0.46 0.73 0.70 0.52 0.33 0.29 0.19 0.14 0.11 0.15
Amortization Expense		 0.02 -0.02 -0.17 -0.02 0.04 0.01 0.77 -1.42 0.00 0.08 0.26
Non-Cash Adjustments To Reconcile Net Income		 2.12 3.09 4.35 5.75 5.99 17 4.11 4.03 6.11 -2.55 -24
Changes in Operating Assets and Liabilities, net		 1.86 2.71 3.48 -0.58 -4.25 -4.44 13 14 -1.14 2.85 16
Net Cash From Investing Activities		 -0.99 -46 25 4.47 14 -0.04 -0.19 -0.04 -0.12 -0.51 -0.13
Net Cash From Continuing Investing Activities		 -0.99 -46 25 4.47 14 -0.04 -0.19 -0.04 -0.12 -0.51 -0.13
Purchase of Property, Plant & Equipment		 -0.99 -1.17 -0.40 -0.31 -0.18 -0.04 -0.19 -0.04 -0.12 -0.51 -0.13
Net Cash From Financing Activities		 31 112 37 21 56 14 37 45 -0.95 26 337
Net Cash From Continuing Financing Activities		 31 112 37 21 56 14 37 45 -0.95 26 337
Issuance of Debt		 0.93 - 9.95 - - - 29 0.00 - 17 0.00
Issuance of Common Equity		 0.00 70 27 21 6.44 14 11 49 2.36 8.71 337
Other Financing Activities, net		 0.75 42 0.53 0.23 50 0.01 0.01 0.01 0.00 0.02 -0.27
Cash Income Taxes Paid		 - - - - - - - - 0.00 0.80 0.10

Quarterly Cash Flow Statements for Cidara Therapeutics

This table details how cash moves in and out of Cidara Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 15 2.45 -1.76 -13 -6.76 135 -37 69 -22 342 -217
Net Cash From Operating Activities		 -11 2.82 -1.63 -13 -6.64 -104 -37 -29 -22 -41 -41
Net Cash From Continuing Operating Activities		 -11 2.82 -1.63 -13 -6.64 -104 -37 -29 -22 -41 -41
Net Income / (Loss) Continuing Operations		 3.01 -14 -9.11 -3.21 -10 -91 -16 -52 -23 -26 -83
Consolidated Net Income / (Loss)		 3.01 -14 -9.11 -3.21 -10 -91 -16 -52 -23 -26 -83
Depreciation Expense		 0.03 0.03 0.02 0.03 0.04 0.04 0.04 0.04 0.04 0.03 0.03
Amortization Expense		 0.48 -0.44 0.01 0.03 0.04 0.19 0.02 0.02 0.01 - -0.17
Non-Cash Adjustments To Reconcile Net Income		 0.65 1.43 1.05 -5.67 -2.33 -24 0.75 1.66 -3.35 -1.34 4.17
Changes in Operating Assets and Liabilities, net		 -15 15 6.39 -3.90 5.94 11 -22 21 4.83 -14 39
Net Cash From Investing Activities		 -0.09 -0.11 -0.13 -0.18 -0.02 - -0.11 - 0.19 - -176
Net Cash From Continuing Investing Activities		 -0.09 -0.11 -0.13 -0.18 -0.02 - -0.11 - 0.19 - -176
Net Cash From Financing Activities		 26 -0.26 - 0.01 -0.09 239 -0.18 98 0.08 383 0.16
Net Cash From Continuing Financing Activities		 26 -0.26 - 0.01 -0.09 239 -0.18 98 0.08 383 0.16
Issuance of Debt		 18 -0.34 - - - - - - - - -1.35
Issuance of Common Equity		 8.63 0.08 - 0.00 - 239 -0.11 98 - - -0.01
Other Financing Activities, net		 0.01 - - 0.01 -0.09 -0.08 -0.08 -0.03 0.08 1.00 1.52

Annual Balance Sheets for Cidara Therapeutics

This table presents Cidara Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 24 110 107 79 79 69 60 75 47 67 215
Total Current Assets		 23 108 105 78 77 66 57 72 45 61 211
Cash & Equivalents		 23 63 85 61 75 50 36 60 33 36 190
Restricted Cash		 - - - - 0.00 10 7.04 2.59 - 0.00 6.35
Short-Term Investments		 0.00 45 19 15 - - - - - - 0.00
Accounts Receivable		 - - 0.00 0.32 - 0.01 11 5.36 5.83 14 1.69
Prepaid Expenses		 0.22 0.70 0.78 2.04 - 5.54 3.07 4.07 6.53 1.71 13
Plant, Property, & Equipment, net		 0.86 1.68 1.37 1.04 0.71 0.43 0.34 0.26 0.22 0.56 0.52
Total Noncurrent Assets		 0.47 0.07 0.19 0.32 1.27 2.73 2.89 3.37 2.17 5.62 3.54
Long-Term Investments		 - - - - - - - - - - 0.00
Noncurrent Note & Lease Receivables		 - - - - - - - - 0.00 0.78 0.70
Other Noncurrent Operating Assets		 0.47 0.07 0.19 0.32 1.27 2.73 2.89 3.37 2.17 3.90 2.84
Total Liabilities & Shareholders' Equity		 24 110 107 79 79 69 60 75 47 67 215
Total Liabilities		 3.25 6.06 19 19 20 31 50 54 62 75 51
Total Current Liabilities		 3.21 5.97 8.91 12 20 30 39 34 41 67 50
Accounts Payable		 1.18 3.10 2.91 2.59 2.85 1.89 4.57 1.30 1.45 3.77 3.61
Accrued Expenses		 1.62 1.42 3.34 4.26 3.88 4.07 7.96 10 7.67 14 13
Current Employee Benefit Liabilities		 0.41 1.46 2.66 2.57 2.82 3.66 4.21 4.86 4.92 5.03 4.91
Other Taxes Payable		 - - - - - - - - 12 18 26
Other Current Liabilities		 - - - 0.00 0.41 0.82 0.94 1.15 1.21 1.30 1.64
Total Noncurrent Liabilities		 33 0.09 9.87 7.21 0.08 0.94 11 20 21 7.82 1.93
Other Noncurrent Operating Liabilities		 33 0.09 0.08 0.00 0.08 0.94 0.00 1.32 0.00 3.58 1.93
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -11 104 88 60 59 38 11 22 -14 -8.21 163
Total Preferred & Common Equity		 -11 104 88 60 59 38 11 22 -14 -8.21 163
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -11 104 88 60 59 38 11 22 -14 -8.21 163
Common Stock		 1.86 149 182 209 278 298 345 399 404 433 775
Retained Earnings		 -13 -45 -94 -149 -219 -260 -335 -377 -419 -441 -611
Accumulated Other Comprehensive Income / (Loss)		 - -0.01 -0.00 -0.01 - - - - - - 0.00

Quarterly Balance Sheets for Cidara Therapeutics

This table presents Cidara Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 67 82 68 63 53 173 162 192 534 519
Total Current Assets		 64 79 62 58 47 169 157 189 532 443
Cash & Equivalents		 53 48 50 49 29 164 127 168 511 294
Restricted Cash		 0.00 - - - - - - 6.34 6.34 6.34
Short-Term Investments		 - - - - - - - - - 126
Accounts Receivable		 5.04 26 5.48 2.86 7.28 2.35 1.70 1.69 1.86 1.86
Prepaid Expenses		 5.78 5.69 4.37 3.71 3.27 1.87 28 13 13 15
Plant, Property, & Equipment, net		 0.17 0.27 0.30 0.58 0.53 0.60 0.56 0.35 0.32 0.29
Total Noncurrent Assets		 2.79 1.98 5.45 5.18 5.35 4.17 5.00 2.53 2.22 76
Long-Term Investments		 - - - - - - - - - 50
Noncurrent Note & Lease Receivables		 - - - - 0.76 0.74 0.72 0.00 0.00 0.00
Other Noncurrent Operating Assets		 2.79 1.98 5.45 5.18 4.59 3.43 4.28 2.53 2.22 25
Total Liabilities & Shareholders' Equity		 67 82 68 63 53 173 162 192 534 519
Total Liabilities		 58 55 53 55 70 42 47 50 33 96
Total Current Liabilities		 33 36 31 36 65 40 44 49 32 96
Accounts Payable		 4.24 3.98 1.90 3.66 5.06 2.29 2.97 4.90 2.21 4.35
Accrued Expenses		 8.16 9.08 10 12 8.24 6.23 8.57 20 11 71
Current Employee Benefit Liabilities		 4.12 5.84 3.58 4.46 5.72 3.51 4.93 1.92 2.63 3.51
Other Taxes Payable		 - - - - 21 26 26 21 15 15
Other Current Liabilities		 1.28 1.00 0.94 1.05 1.46 1.52 1.58 1.44 1.50 1.56
Total Noncurrent Liabilities		 25 19 21 20 5.07 2.78 2.36 1.24 0.84 0.42
Other Noncurrent Operating Liabilities		 0.34 - 3.60 3.31 3.18 2.78 2.36 1.24 0.84 0.42
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.07 27 15 8.04 -18 131 116 142 501 422
Total Preferred & Common Equity		 9.07 27 15 8.04 -18 131 116 142 501 422
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 9.07 27 15 8.04 -18 131 116 142 501 422
Common Stock		 403 431 432 432 434 674 675 776 1,162 1,166
Retained Earnings		 -394 -404 -416 -424 -452 -543 -559 -635 -660 -744
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - - - -0.11

Annual Metrics And Ratios for Cidara Therapeutics

This table displays calculated financial ratios and metrics derived from Cidara Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -42.30% 310.81% 30.01% -63.87% -94.52%
EBITDA Growth		 -851.15% -174.66% -50.21% -14.96% -7.34% 30.64% -72.77% 38.58% 23.72% 19.01% -553.96%
EBIT Growth		 -845.24% -173.70% -49.90% -15.04% -7.04% 30.74% -73.91% 41.19% 21.16% 18.77% -550.78%
NOPAT Growth		 -974.21% -178.01% -49.90% -15.04% -13.57% 34.07% -72.20% 41.19% 20.71% 19.23% -550.78%
Net Income Growth		 -784.97% -170.67% -49.61% -15.70% -5.90% 30.37% -75.49% 41.11% 20.92% 31.72% -640.60%
EPS Growth		 -249.64% 77.60% -2.15% 4.22% 15.72% 48.88% -31.39% 55.00% 40.74% 31.72% -409.52%
Operating Cash Flow Growth		 -635.69% -236.69% -53.21% -25.49% -13.62% 49.68% -90.70% 53.63% -12.84% 21.22% -686.97%
Free Cash Flow Firm Growth		 0.00% -304.02% 42.05% -29.46% -11.38% 50.04% -68.89% 55.58% 13.72% -183.55% -183.53%
Invested Capital Growth		 0.00% 89.48% -84.51% 14.28% 3.55% -126.90% -102.21% -51.16% -23.77% 46.36% -29.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 9.50% 18.85% 7.59% 5.15% -54.16% -96.05%
EBITDA Q/Q Growth		 0.00% -19.59% -10.20% 1.60% 0.72% -3.85% -10.48% 4.18% 0.65% 0.86% -25.76%
EBIT Q/Q Growth		 0.00% -19.53% -10.05% 1.58% 0.83% -3.84% -11.60% 10.16% -0.27% -6.17% -25.68%
NOPAT Q/Q Growth		 0.00% -19.53% -10.05% 1.58% -5.22% 5.69% -11.60% 10.16% -0.85% -6.17% -25.68%
Net Income Q/Q Growth		 0.00% -19.35% -10.37% 1.70% 1.81% -4.27% -11.80% 10.21% -1.08% 37.82% -40.66%
EPS Q/Q Growth		 0.00% 72.60% -322.82% 6.47% 12.99% 0.00% 0.00% 18.18% 2.04% 37.82% -45.46%
Operating Cash Flow Q/Q Growth		 0.00% -15.92% -14.34% 4.29% -7.95% -5.67% 6.96% -17.62% -27.24% 26.96% -10.44%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -13.43% 3.25% -18.97% 9.20% 14.63% -49.65% 15.37% -92.31% 8.86%
Invested Capital Q/Q Growth		 0.00% -100.89% -23.21% -52.86% 34.75% 16.34% -57.71% -0.92% -7.18% 37.73% -179.59%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -195.92% -586.67% -87.71% -51.47% -115.38% -13,779.22%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -199.49% -595.42% -85.24% -51.98% -116.22% -13,811.92%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -197.53% -595.42% -85.24% -51.69% -116.22% -13,811.92%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -196.47% -597.59% -85.67% -52.11% -98.49% -13,319.76%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.82% 91.49% 99.73%
Interest Burden Percent		 100.75% 99.63% 99.44% 100.01% 98.95% 99.47% 100.36% 100.50% 100.00% 92.63% 96.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 103.92% -69.63% -50.15% -75.35% -99.28% -84.75% -297.06% -263.05% -941.39% 202.50% -218.99%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -55.80% -111.05% -62.25% -54.25% -47.26% -124.97%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -55.50% -111.45% -62.57% -54.69% -40.05% -120.52%
Return on Common Equity (ROCE)		 103.92% -69.63% -50.15% -75.35% -99.28% -84.75% -297.06% -263.05% -941.39% 202.50% -218.99%
Return on Equity Simple (ROE_SIMPLE)		 103.92% -30.98% -54.62% -93.28% -99.79% -108.61% -672.99% -196.85% 232.61% 279.31% -103.99%
Net Operating Profit after Tax (NOPAT)		 -8.14 -23 -34 -39 -44 -29 -50 -30 -23 -19 -123
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -139.65% -416.79% -59.67% -36.39% -81.36% -9,668.35%
Net Nonoperating Expense Percent (NNEP)		 -32.97% -14.69% -14.10% -20.87% -22.63% -20.68% -50.60% -26.96% -21.93% -16.01% -43.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 230.72% -75.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 77.64% 131.76% 37.80% 31.88% 58.33% 1,616.86%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 221.86% 563.66% 147.44% 120.10% 157.90% 12,295.06%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 299.49% 695.42% 185.24% 151.98% 216.22% 13,911.92%
Earnings before Interest and Taxes (EBIT)		 -12 -32 -48 -56 -60 -41 -72 -42 -33 -27 -176
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -32 -48 -55 -59 -41 -71 -43 -33 -27 -176
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 2.27 1.97 2.30 1.10 3.35 8.20 3.93 0.00 0.00 1.16
Price to Tangible Book Value (P/TBV)		 0.00 2.27 1.97 2.30 1.10 3.35 8.20 3.93 0.00 0.00 1.16
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 6.07 7.28 1.71 0.84 3.08 148.56
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 3.66 4.31 0.50 0.33 1.55 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.11 0.17 0.17 0.26 0.66 0.12 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.11 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 1.99 -1.41 -1.05 -1.08 -1.09 -1.19 -1.78 -2.96 -12.95 2.20 -1.38
Leverage Ratio		 -2.13 1.45 1.13 1.26 1.33 1.53 2.67 4.20 17.21 -5.06 1.82
Compound Leverage Factor		 -2.14 1.45 1.12 1.26 1.32 1.52 2.68 4.23 17.21 -4.68 1.76
Debt to Total Capital		 0.00% 0.00% 10.00% 14.18% 14.37% 20.85% 39.59% 10.72% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 3.83% 14.37% 20.85% 39.59% 10.72% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 10.00% 10.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 90.00% 85.82% 85.63% 79.15% 60.41% 89.28% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 -0.20 -0.18 -0.17 -0.24 -0.10 -0.06 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 1.98 1.19 1.09 1.23 0.51 1.37 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.20 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.29 -0.25 -0.22 -0.34 -0.14 -0.09 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 2.80 1.68 1.46 1.72 0.71 2.02 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.29 -0.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 22.87 3.90 0.30 -3.53 -3.88 -10.05 -6.66 -12.68 -9.75 -3.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.16 18.11 11.83 6.43 3.88 2.18 1.48 2.11 1.09 0.90 4.25
Quick Ratio		 7.09 18.00 11.74 6.26 3.75 1.66 1.22 1.91 0.93 0.74 3.86
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 26 -53 -31 -40 -45 -22 -38 -17 -14 -41 -116
Operating Cash Flow to CapEx		 -778.00% -2,218.72% -9,917.96% -16,310.13% -32,036.72% -81,520.00% -29,253.23% -61,541.46% -24,129.66% -4,441.98% -136,847.29%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.28 0.19 0.73 1.05 0.41 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 2.16 6.00 11.52 2.34 0.16
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 36.66 31.30 165.79 269.66 59.78 2.37
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 169.16 60.86 31.68 156.05 2,257.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 169.16 60.86 31.68 156.05 2,257.13
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -34 -3.60 -6.65 -5.70 -5.50 -12 -25 -38 -47 -25 -33
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 -2.33 -0.64 -1.57 -1.51 -0.64 -0.04
Increase / (Decrease) in Invested Capital		 -34 31 -3.04 0.95 0.20 -6.97 -13 -13 -9.06 22 -7.57
Enterprise Value (EV)		 0.00 128 79 72 0.58 77 52 25 21 36 -6.76
Market Capitalization		 0.00 235 173 138 65 127 88 85 54 72 189
Book Value per Share		 ($13.96) $7.57 $5.29 $2.95 $2.13 $1.15 $0.24 $0.32 ($0.20) ($0.09) $23.18
Tangible Book Value per Share		 ($13.96) $7.57 $5.29 $2.95 $2.13 $1.15 $0.24 $0.32 ($0.20) ($0.09) $23.18
Total Capital		 -11 104 98 70 69 48 18 24 -14 -8.21 163
Total Debt		 0.00 0.00 9.79 9.87 9.93 9.97 7.02 2.59 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 9.79 7.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -23 -108 -95 -65 -65 -50 -36 -60 -33 -36 -196
Capital Expenditures (CapEx)		 0.99 1.17 0.40 0.31 0.18 0.04 0.19 0.04 0.12 0.51 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.00 -5.27 -8.13 -7.06 -7.40 -15 -17 -22 -29 -42 -35
Debt-free Net Working Capital (DFNWC)		 20 102 96 68 67 46 26 40 3.69 -6.56 161
Net Working Capital (NWC)		 20 102 96 66 57 36 19 38 3.69 -6.56 161
Net Nonoperating Expense (NNE)		 3.76 9.57 14 17 15 12 22 13 10 3.99 47
Net Nonoperating Obligations (NNO)		 -23 -108 -95 -65 -65 -50 -36 -60 -33 -17 -196
Total Depreciation and Amortization (D&A)		 0.20 0.44 0.56 0.69 0.57 0.34 1.06 -1.23 0.14 0.20 0.42
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% -70.23% -143.36% -44.38% -45.05% -181.85% -2,744.63%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 217.93% 212.56% 81.24% 5.73% -28.19% 12,641.80%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 170.28% 154.36% 76.01% 5.73% -28.19% 12,641.80%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($290.20) ($65.00) ($66.40) ($63.60) ($55.20) ($28.20) ($36.00) ($16.20) ($8.60) ($5.20) ($26.75)
Adjusted Weighted Average Basic Shares Outstanding		 40.99K 691.14K 840.06K 1.04M 1.39M 2.03M 2.40M 2.62M 3.49M 4.37M 6.35M
Adjusted Diluted Earnings per Share		 ($290.20) ($65.00) ($66.40) ($63.60) ($55.20) ($28.20) ($36.00) ($16.20) ($8.60) ($5.20) ($26.75)
Adjusted Weighted Average Diluted Shares Outstanding		 40.99K 691.14K 840.06K 1.04M 1.39M 2.03M 2.40M 2.62M 3.49M 4.37M 6.35M
Adjusted Basic & Diluted Earnings per Share		 ($290.20) ($65.00) ($66.40) ($63.60) ($55.20) ($28.20) ($36.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.99K 496.02K 724.45K 875.04K 1.26M 1.45M 2.08M 3.41M 4.45M 0.00 10.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.14 -23 -34 -39 -44 -29 -50 -30 -23 -19 -123
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -139.65% -416.79% -59.67% -36.39% -81.36% -9,668.35%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -196.47% -597.59% -85.67% -51.69% -107.65% -13,356.16%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.96% 0.00% 0.00% -0.14% 0.00% -0.08% 0.00% 0.00% -2.14% 0.00% 0.00%

Quarterly Metrics And Ratios for Cidara Therapeutics

This table displays calculated financial ratios and metrics derived from Cidara Therapeutics' official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 267.24% -18.11% -77.38% -265.05% -96.27% -94.07% -100.00% 56.28% -100.00% -100.00% 0.00%
EBITDA Growth		 118.30% 46.34% -126.41% 1.24% -357.60% -1,237.79% -291.00% -180.00% -199.06% 71.43% -412.12%
EBIT Growth		 115.23% 48.56% -129.83% -9.22% -407.16% -1,322.41% -289.30% -179.37% -197.11% 71.47% -409.53%
NOPAT Growth		 121.76% 48.54% -120.96% -9.22% -315.01% -1,322.41% -289.30% -179.37% -195.82% 71.47% -409.53%
Net Income Growth		 116.48% -3.85% -160.80% 81.28% -442.71% -569.47% -75.52% -1,527.98% -127.39% 71.80% -420.69%
EPS Growth		 116.48% -3.85% -160.80% 81.28% -442.71% -561.92% -21.29% -1,296.61% 27.19% 91.75% -26.53%
Operating Cash Flow Growth		 53.84% 123.84% -105.84% 39.42% 39.03% -3,777.53% -2,145.72% -131.21% -230.37% 60.53% -10.68%
Free Cash Flow Firm Growth		 65.76% 74.62% -130.73% -1,113.48% 358.53% -2,883.29% -530.93% 17.33% -260.98% 46.42% 52.10%
Invested Capital Growth		 32.96% -7.42% 7.68% 46.36% -121.38% 4.55% 71.07% -29.91% 29.90% 52.91% -360.45%
Revenue Q/Q Growth		 151.54% -80.50% 81.08% -285.86% 105.68% -96.43% -100.00% 0.00% 100.00% 0.00% 0.00%
EBITDA Q/Q Growth		 117.49% -317.70% 38.07% -318.72% 54.37% -801.77% 81.90% -199.86% 51.26% -8.00% -224.47%
EBIT Q/Q Growth		 116.31% -342.65% 33.79% -316.85% 54.14% -797.80% 81.88% -199.14% 51.23% -7.90% -223.65%
NOPAT Q/Q Growth		 123.30% -269.85% 33.79% -316.85% 54.14% -797.80% 81.88% -199.14% 51.44% -8.37% -223.65%
Net Income Q/Q Growth		 117.56% -552.17% 33.15% 64.72% -221.38% -783.29% 82.47% -227.23% 55.11% -9.53% -223.64%
EPS Q/Q Growth		 117.56% -552.17% 33.15% 64.72% -221.38% -776.75% 87.74% -236.33% 79.85% 0.60% -87.88%
Operating Cash Flow Q/Q Growth		 48.11% 125.89% -157.90% -678.58% 47.78% -1,462.01% 64.64% 19.84% 25.38% -86.61% 0.84%
Free Cash Flow Firm Q/Q Growth		 -164.64% 69.71% -182.21% -436.45% 156.38% -478.44% 40.32% 29.71% -9.78% -16.32% 46.63%
Invested Capital Q/Q Growth		 55.18% -65.65% -16.04% 37.73% -84.96% 28.58% 64.83% -179.59% 0.19% 52.02% -243.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 12.59% -140.63% -48.10% 0.00% -870.50% -31,708.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 10.65% -132.57% -48.48% 0.00% -877.90% -31,782.78% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 10.65% -132.57% -48.48% 0.00% -877.90% -31,782.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 11.54% -267.66% -98.81% 0.00% -1,061.25% -30,201.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 222.43% 236.24% 17.75% 126.28% 96.81% 102.90% 104.16% 100.00% 100.00% 100.00%
Interest Burden Percent		 108.34% 90.77% 86.28% 97.17% 95.73% 98.15% 89.31% 96.52% 92.52% 93.92% 93.91%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -77.31% -343.35% -431.22% 202.50% -800.93% -155.59% -195.25% -218.99% -295.36% -37.17% -68.67%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 12.97% -203.02% -37.79% 0.00% 0.00% -10,923.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 14.06% -409.90% -77.02% 0.00% 0.00% -10,379.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -77.31% -343.35% -431.22% 202.50% -800.93% -155.59% -195.25% -218.99% -295.36% -37.17% -68.67%
Return on Equity Simple (ROE_SIMPLE)		 -45.80% -83.01% -458.82% 0.00% 203.99% -86.95% -104.41% 0.00% -129.15% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 2.78 -4.72 -3.13 -13 -5.98 -67 -12 -36 -18 -19 -62
NOPAT Margin		 10.65% -92.80% -33.93% 0.00% -614.53% -22,247.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.55% -23.71% -11.75% 39.44% -11.29% -22.37% -4.33% -14.90% -5.69% -1.92% -7.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - 158.80% 33.63% - - -22.30% -12.48% -3.82% -14.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 17.07% 62.50% 35.79% 0.00% 369.58% 1,571.52% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 72.28% 170.08% 112.68% 0.00% 608.32% 30,311.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 89.35% 232.57% 148.48% 0.00% 977.90% 31,882.78% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 2.78 -6.75 -4.47 -19 -8.54 -96 -17 -52 -25 -27 -89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.29 -7.16 -4.43 -19 -8.47 -96 -17 -52 -25 -27 -89
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.21 6.60 10.58 0.00 0.00 0.42 0.65 1.16 1.67 1.26 5.75
Price to Tangible Book Value (P/TBV)		 4.21 6.60 10.58 0.00 0.00 0.42 0.65 1.16 1.67 1.26 5.75
Price to Revenue (P/Rev)		 1.35 1.24 1.67 3.08 0.00 1.31 2.35 148.56 781.25 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.78 0.62 0.72 1.55 0.00 0.00 0.00 0.00 203.47 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.66 -10.07 -5.95 2.20 -8.50 -1.47 -1.42 -1.38 -1.64 -1.08 -1.12
Leverage Ratio		 4.31 14.43 7.62 -5.06 14.85 1.65 1.83 1.82 1.97 1.12 1.27
Compound Leverage Factor		 4.67 13.09 6.57 -4.91 14.21 1.62 1.63 1.75 1.83 1.05 1.19
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.90 -5.98 -7.45 -9.33 -12.28 -4.31 -3.17 -1.67 -1.36 10.66 13.37
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.23 1.98 1.62 0.90 0.72 4.25 3.54 4.25 3.87 16.45 4.62
Quick Ratio		 2.07 1.78 1.45 0.74 0.55 4.21 2.91 3.86 3.48 15.86 4.40
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.61 -2.31 -6.51 -35 20 -69 -41 -29 -32 -37 -20
Operating Cash Flow to CapEx		 -11,593.62% 2,637.38% -1,296.83% -7,147.19% -28,886.96% 0.00% -34,617.92% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.22 1.53 0.78 0.41 0.00 0.34 0.29 0.01 0.00 0.00 0.00
Accounts Receivable Turnover		 4.82 15.96 12.86 2.34 0.00 10.59 14.17 0.16 0.07 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 327.88 330.60 134.91 59.78 0.00 92.26 56.54 2.37 0.68 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 75.69 22.87 28.37 156.05 0.00 34.46 25.77 2,257.13 5,423.63 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 75.69 22.87 28.37 156.05 0.00 34.46 25.77 2,257.13 5,423.63 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -21 -35 -41 -25 -47 -33 -12 -33 -33 -16 -54
Invested Capital Turnover		 -3.17 -2.44 -1.20 -0.64 0.00 -1.21 -1.23 -0.04 -0.01 0.00 0.00
Increase / (Decrease) in Invested Capital		 10 -2.42 3.38 22 -26 1.59 29 -7.57 14 18 -42
Enterprise Value (EV)		 65 51 36 36 54 -110 -52 -6.76 61 115 1,952
Market Capitalization		 113 102 85 72 83 54 76 189 236 632 2,428
Book Value per Share		 $0.30 $0.17 $0.09 ($0.09) ($0.20) $28.70 $16.43 $23.18 $12.93 $38.64 $16.66
Tangible Book Value per Share		 $0.30 $0.17 $0.09 ($0.09) ($0.20) $28.70 $16.43 $23.18 $12.93 $38.64 $16.66
Total Capital		 27 15 8.04 -8.21 -18 131 116 163 142 501 422
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -48 -50 -49 -36 -29 -164 -127 -196 -174 -517 -477
Capital Expenditures (CapEx)		 0.09 0.11 0.13 0.18 0.02 0.00 0.11 0.00 -0.19 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.15 -20 -27 -42 -48 -35 -15 -35 -34 -17 -79
Debt-free Net Working Capital (DFNWC)		 44 31 22 -6.56 -19 129 112 161 140 499 347
Net Working Capital (NWC)		 44 31 22 -6.56 -19 129 112 161 140 499 347
Net Nonoperating Expense (NNE)		 -0.23 8.90 5.98 -9.82 4.35 24 3.81 16 5.79 6.55 21
Net Nonoperating Obligations (NNO)		 -48 -50 -49 -17 -29 -164 -127 -196 -174 -517 -477
Total Depreciation and Amortization (D&A)		 0.51 -0.41 0.04 0.06 0.07 0.23 0.06 0.06 0.05 0.03 -0.14
Debt-free, Cash-free Net Working Capital to Revenue		 -4.97% -23.82% -52.34% -181.85% 0.00% -85.41% -46.36% -2,744.63% -11,407.28% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 52.52% 37.44% 43.48% -28.19% 0.00% 310.91% 348.56% 12,641.80% 46,370.53% 0.00% 0.00%
Net Working Capital to Revenue		 52.52% 37.44% 43.48% -28.19% 0.00% 310.91% 348.56% 12,641.80% 46,370.53% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.60 ($2.80) ($1.80) ($11.80) ($2.28) ($19.99) ($2.45) ($8.24) ($1.66) ($1.65) ($3.10)
Adjusted Weighted Average Basic Shares Outstanding		 3.93M 4.51M 4.51M 218.57K 4.54M 4.56M 6.53M 6.35M 14.18M 15.55M 26.88M
Adjusted Diluted Earnings per Share		 $0.60 ($2.80) ($1.80) ($11.80) ($2.28) ($19.99) ($2.45) ($8.24) ($1.66) ($1.65) ($3.10)
Adjusted Weighted Average Diluted Shares Outstanding		 5.06M 4.51M 4.51M 218.57K 4.54M 4.56M 6.53M 6.35M 14.18M 15.55M 26.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($11.80) $0.00 $0.00 $0.00 ($8.24) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.50M 4.51M 4.52M 0.00 4.56M 7.04M 7.05M 10.95M 12.97M 25.36M 31.44M
Normalized Net Operating Profit after Tax (NOPAT)		 1.95 -4.72 -3.13 -13 -5.98 -67 -12 -36 -18 -19 -62
Normalized NOPAT Margin		 7.46% -92.80% -33.93% 0.00% -614.53% -22,247.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 11.54% -120.33% -41.82% 0.00% -840.39% -31,195.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Cidara Therapeutics (NASDAQ: CDTX) has shown a pattern of ongoing cash burn and net losses over the last four years, but also significant financing activity that has boosted liquidity at various points. Below are the key takeaways focused on the latest four years of quarterly data provided (2022 through 2025), with positive items listed first, followed by neutral, then negative items.

  • Significant equity financing in 2025: Net cash from continuing financing activities was about $383.4 million in Q2 2025, helping to massively bolster the company’s cash runway and overall equity base.
  • Additional financing support in late 2024: Net cash from continuing financing activities was about $98.2 million in Q4 2024, contributing to liquidity without immediate revenue generation.
  • Rising total equity driven by financings: Total equity reached roughly $501.2 million by Q2 2025, reflecting successful capital raises that support ongoing development work.
  • Improved asset liquidity from capital infusions: Total assets rose to about $534.3 million by Q2 2025, primarily due to cash raised from financing activities, enhancing liquidity for operations and R&D.
  • Strong cash balance at times in 2025: Cash & equivalents stood around $510.6 million in Q2 2025, providing a substantial liquidity cushion amid continued operating and investing outlays.
  • No material operating revenue observed in the latest years: Operating revenue remains effectively zero across multiple quarters, consistent with a biotech company in development-stage trials rather than commercial sales.
  • High ongoing research and development and SG&A costs: R&D expenses and SG&A are substantial in several periods, reflecting early-stage drug development and general corporate expenses typical for biotech companies.
  • Retained earnings consistently negative: Retained earnings are deeply negative in recent quarters (e.g., roughly -$743.7 million in Q3 2025), indicating accumulated losses that financing has been used to offset rather than generate profits.
  • Persistent net losses: Net income attributable to common shareholders remains negative across the quarters shown (for example, -$83.2 million in Q3 2025 on a consolidated basis, and substantial losses in prior quarters), highlighting ongoing profitability challenges.
  • Long-running cash burn from operations and investing: Operating cash flow has been negative in every quarter presented (e.g., -$40.6 million in Q3 2025 and similar levels in prior periods), and net investing cash flow has been heavily negative in several quarters (large outlays in 2025), underscoring the burn required to advance development without revenue.
05/06/26 07:30 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Cidara Therapeutics' Financials

When does Cidara Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Cidara Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cidara Therapeutics' net income changed over the last 10 years?

Cidara Therapeutics' net income appears to be on an upward trend, with a most recent value of -$169.83 million in 2024, rising from -$11.89 million in 2014. The previous period was -$22.93 million in 2023. Find out what analysts predict for Cidara Therapeutics in the coming months.

What is Cidara Therapeutics' operating income?
Cidara Therapeutics' total operating income in 2024 was -$176.10 million, based on the following breakdown:
  • Total Gross Profit: $1.28 million
  • Total Operating Expenses: $177.38 million
How has Cidara Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Cidara Therapeutics' total revenue changed from $0.00 in 2014 to $1.28 million in 2024, a change of 127,500,000.0%.

How much debt does Cidara Therapeutics have?

Cidara Therapeutics' total liabilities were at $51.49 million at the end of 2024, a 31.6% decrease from 2023, and a 1,485.7% increase since 2014.

How much cash does Cidara Therapeutics have?

In the past 10 years, Cidara Therapeutics' cash and equivalents has ranged from $22.80 million in 2014 to $189.83 million in 2024, and is currently $189.83 million as of their latest financial filing in 2024.

How has Cidara Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Cidara Therapeutics' book value per share changed from -13.96 in 2014 to 23.18 in 2024, a change of -266.0%.


Related Companies

Financial statements for NASDAQ:CDTX last updated on 11/14/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel